# Pembrolizumab in Hepatocellular Carcinoma

> **NCT03419481** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **CCTU** · enrollment: 30 (actual)

## Conditions studied

- HCC

## Interventions

- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT03419481
- **Lead sponsor:** CCTU
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03419481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03419481, "Pembrolizumab in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03419481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*